Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CORMEDIX INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 3.540 USD | -4.32% | -4.07% | -16.11% | |
Financials (USD)
| Sales 2023 * | 0 M | Sales 2024 * | 37 M | Capitalization | 203 M |
|---|---|---|---|---|---|
| Net income 2023 * | -51 M | Net income 2024 * | -42 M | EV / Sales 2023 * | -591x |
| Net cash position 2023 * | 55 M | Net cash position 2024 * | 43 M | EV / Sales 2024 * | 4,34x |
| P/E ratio 2023 * | -3,62x | P/E ratio 2024 * | -5,19x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.11% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -4.32% | ||
| 1 week | -4.07% | ||
| Current month | -4.32% | ||
| 1 month | -10.38% | ||
| 3 months | -9.23% | ||
| 6 months | -18.24% | ||
| Current year | -16.11% |
1 week
3.52
3.79
1 month
3.524.18
Current year
3.206.09
1 year
2.716.09
3 years
2.6518.80
5 years
2.1618.80
10 years
0.8652.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 47 | 2022 |
Mathew David
DFI | Director of Finance/CFO | 46 | 2020 |
| Chief Tech/Sci/R&D Officer | 44 | 2018 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
BRD | Director/Board Member | 47 | 2022 |
Myron Kaplan
CHM | Chairman | 78 | 2017 |
Steven Lefkowitz
BRD | Director/Board Member | 67 | 2017 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 293,477 M$ | +10.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-10-02 | 3.540 | -4.32% | 482,871 |
| 23-09-29 | 3.700 | +0.27% | 530,016 |
| 23-09-28 | 3.690 | +0.54% | 506,838 |
| 23-09-27 | 3.670 | +0.27% | 342,452 |
| 23-09-26 | 3.660 | -0.81% | 372,237 |
Delayed Quote Nasdaq, October 02, 2023 at 04:00 pm EDT
More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
2023-10-26
- Annual General Meeting
Trading Rating :
Investor Rating :
ESG Refinitiv :
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.700USD
Average target price
13.75USD
Spread / Average Target
+271.62%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -16.11% | 203 M $ | |
| -63.40% | 128 M $ | |
| +47.83% | 277 M $ | |
| +145.28% | 110 M $ | |
| +51.79% | 78 M $ | |
| +68.79% | 849 M $ | |
| +67.38% | 2 541 M $ | |
| +55.64% | 190 M $ | |
| +19.56% | 5 015 M $ | |
| +32.52% | 4 011 M $ |
